The role of cytoreductive nephrectomy in elderly patients with metastatic kidney cancer

The role of cytoreductive nephrectomy for metastatic renal cell cancer (RCC) is not clearly understood, particularly since the advent of targeted therapies. Data are conflicting, and the use of cytoreductive nephrectomy in the elderly people with metastatic RCC is not well defined. A recent study compared survival between patients with metastatic RCC who underwent cytoreductive […]

read more

European Commission approves cabozantinib for first-line kidney cancer

The European Commission has approved cabozantinib (Cabometyx) for the first-line treatment of advanced renal cell carcinoma (RCC).  The approval is based on data from the CABOSUN trial, which demonstrated that cabozantinib significantly prolongs progression-free survival (PFS) compared to sunitinib in people with untreated advanced RCC at intermediate or poor-risk of the cancer spreading. Cabozantinib, a […]

read more

Results from a major study might lead to reduced animal testing by pharmaceutical companies

A major, groundbreaking study carried out by Elsevier, a global informatics company, in partnership with Bayer pharmaceuticals, investigating how well animal studies predict human safety may lead to reduced animal testing and better clinical results for patients. Researchers investigated the consistency between preclinical animal testing and observations made in human clinical trials. They looked at […]

read more

Depleted levels of metabolic enzymes promote kidney cancer tumour growth

Researchers at the University of Pennsylvania in Philadelphia, USA, have discovered that enzymes important in multiple metabolic pathways are depleted in clear cell renal cell carcinoma (RCC) tumours. They published their findings last week in the journal Cell Metabolism. Their research looked at the function of essential metabolic enzymes in the light of the genetic, protein, […]

read more

Cabozantinib significantly improves overall survival in people with previously treated advanced kidney cancer

Cabozantinib significantly improves overall survival in previously treated patients with advanced renal cell carcinoma (RCC) compared to everolimus, with consistent results after long-term follow-up. Results from a second interim analysis of the phase 3 METEOR trial have been published in the British Journal of Cancer, showing cabozantinib significantly improved overall survival compared with everolimus in […]

read more

NHS to cut clinical trial bureaucracy to improve access to cutting-edge therapies

The NHS has introduced new processes to fast track research and improve access to cutting-edge therapies for patients by reducing the bureaucracy surrounding clinical trials. This bureaucracy has often been a barrier to getting hospitals to sign-up to multi-centre trials. The government has already created the Health Research Authority (HRA) as a single port of […]

read more

FDA grants Fast Track designation to glutaminase inhibitor combination for metastatic kidney cancer

The glutaminase inhibitor, CB-839 has been granted Fast Track designation by the US Food and Drug Administration (FDA) in combination with cabozantinib (Cabometyx) for the treatment of people with metastatic renal cell carcinoma (mRCC) who have previously received one or two drug treatments. The FDA’s Fast Track programme speeds up the development, review and approval […]

read more

Belief in fake causes of cancer is rife in England

A Cancer Research UK survey of 1,330 people in England found that more than 40% wrongly thought stress and food additives were causes of cancer, while about a third incorrectly believed that electromagnetic frequencies and eating genetically modified (GM) food were risk factors. Others thought cancer was caused by microwave ovens and drinking from plastic […]

read more

UK patient groups say that pharma could be more transparent

An independent study of the views of 83 UK-based patient groups on the corporate reputation of 15 pharmaceutical companies, and of the pharma industry as a whole, reported a lack of transparency at sharing clinical data. The study was conducted by PatientView, and collected the opinions of patient groups in a survey conducted between November […]

read more

Kidney cancer vaccine abandoned after failure of phase 3 clinical trial

Argos Therapeutics has abandoned its phase 3 trial of rocapuldencel-T (a kidney cancer vaccine) in combination with sunitinib in patients with newly diagnosed metastatic renal cell carcinoma (mRCC) due to lack of efficacy. Last year, an independent data monitoring committee (IDMC) recommended that the phase 3 ADAPT trial exploring rocapuldencel-T (AGS-003) for the first-line treatment of mRCC be stopped because […]

read more
Showing 1 to 10 of 296 results
  TOP